Description
OB FUNDS INFECTIOUS DISEASE REFERENCE LAB TESTING
Base award description: IGF::OT::IGF INFECTIOUS DISEASE REFERENCE LAB TESTING BASE PERIOD (4/1/15 - 9/30/15) 1ST OPTION PERIOD (10/1/15 - 9/30/16) 2ND OPTION PERIOD (10/1/16 - 9/30/17) 3RD OPTION PERIOD (10/1/17 - 9/30/18) 4TH OPTION PERIOD (10/1/18 - 9/30/19)
Modification chain · 20 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2015-03-17+$11,696= $11,696
- Mod P000012015-08-20+$5,759= $17,455
- Mod P000022015-10-01+$22,946= $40,400
- Mod P000032015-10-13+$424= $40,824
- Mod P000042016-10-01+$23,566= $64,389
- Mod P000052017-04-07-$564= $63,826
- Mod P000072017-09-22+$14,000= $77,826
- Mod P000062017-10-01+$24,242= $102,068
- Mod P000082018-09-06+$41,926= $143,994
- Mod P000092018-10-01+$24,900= $168,894
- Mod P000102019-04-26-$4,549= $164,346
- Mod P000112019-05-14+$15,000= $179,346
- Mod P000122019-10-01+$15,441= $194,787
- Mod P000132019-12-17+$15,441= $210,228
- Mod P000142020-04-01+$0= $210,228
- Mod P000162020-05-27+$0= $210,228
- Mod P000152020-06-18-$17,365= $192,862
- Mod P000172021-04-27+$3,612= $196,475
- Mod P000182022-03-22+$2,849= $199,324
- Mod P000192022-04-18+$17,092= $216,416
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2015-03-17 | +$11,696 | $11,696 | IGF::OT::IGF INFECTIOUS DISEASE REFERENCE LAB TESTING BASE PERIOD (4/1/15 - 9/30/15) 1ST OPTION PERIOD (10/1/1… |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2015-08-20 | +$5,759 | $17,455 | IGF::OT::IGF P00001 - ADDITIONAL WORK WITHIN SCOPE. INFECTIOUS DISEASE REFERENCE LAB TESTING BASE PERIOD (4/1/… |
| Mod P00002· EXERCISE AN OPTION | 2015-10-01 | +$22,946 | $40,400 | IGF::OT::IGF P00001 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15 - 9/30/16) INFECTIOUS DISEASE REFERENC… |
| Mod P00003· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2015-10-13 | +$424 | $40,824 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00004· EXERCISE AN OPTION | 2016-10-01 | +$23,566 | $64,389 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00005· CHANGE ORDER | 2017-04-07 | −$564 | $63,826 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00007· FUNDING ONLY ACTION | 2017-09-22 | +$14,000 | $77,826 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00006· EXERCISE AN OPTION | 2017-10-01 | +$24,242 | $102,068 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00008· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2018-09-06 | +$41,926 | $143,994 | ADDITIONAL FUNDS |
| Mod P00009· EXERCISE AN OPTION | 2018-10-01 | +$24,900 | $168,894 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00010· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2019-04-26 | −$4,549 | $164,346 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00011· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2019-05-14 | +$15,000 | $179,346 | IGF::OT::IGF P00003 - ADDITIONAL WORK WITHIN SCOPE. P00002 EXERCISES OPTION CLINS 1001AA - 1001AZ (POP 10/1/15… |
| Mod P00012· EXERCISE AN OPTION | 2019-10-01 | +$15,441 | $194,787 | P00004 - 3 MONTH EXTENSION TO CONTINUE SERVICES INFECTIOUS DISEASE REFERENCE LAB TESTING |
| Mod P00013· EXERCISE AN OPTION | 2019-12-17 | +$15,441 | $210,228 | P00004 - 3 MONTH EXTENSION TO CONTINUE SERVICES INFECTIOUS DISEASE REFERENCE LAB TESTING |
| Mod P00014· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-04-01 | +$0 | $210,228 | EXTENSION TO CONTINUE SERVICES INFECTIOUS DISEASE REFERENCE LAB TESTING |
| Mod P00016· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-05-27 | +$0 | $210,228 | EXTENSION TO CONTINUE SERVICES INFECTIOUS DISEASE REFERENCE LAB TESTING |
| Mod P00015· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2020-06-18 | −$17,365 | $192,862 | EXTENSION TO CONTINUE SERVICES INFECTIOUS DISEASE REFERENCE LAB TESTING |
| Mod P00017· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2021-04-27 | +$3,612 | $196,475 | OB FUNDS INFECTIOUS DISEASE REFERENCE LAB TESTING |
| Mod P00018· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-03-22 | +$2,849 | $199,324 | OB FUNDS INFECTIOUS DISEASE REFERENCE LAB TESTING |
| Mod P00019· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-04-18 | +$17,092 | $216,416 | OB FUNDS INFECTIOUS DISEASE REFERENCE LAB TESTING |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI WLDGTNCFFJZ3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26126P0043 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · Q301 · REFERENCE LABORATORY TESTING | $64,000 | FY2026 |
| 36C26125N0128 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · Q301 · REFERENCE LABORATORY TESTING | $63,377 | FY2025 |
| 36C26124C0032 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · U099 · EDUCATION/TRAINING- OTHER | $155,954 | FY2024 |
| 36C26124N0073 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · Q301 · REFERENCE LABORATORY TESTING | $85,727 | FY2024 |
| 36C26123C0013 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · AN44 · HEALTH R&D SERVICES; HEALTH CARE - OTHER; R&D ADMINISTRATIVE EXPENSES | $181,361 | FY2023 |
| 36C26123N0064 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · Q301 · REFERENCE LABORATORY TESTING | $56,773 | FY2023 |
Other recipients under Q301 from 261-NETWORK CONTRACT OFFICE 21 (36C261) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26126P0942 | PACIFIC BIOLABS INC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,304 | FY2026 |
| 36C26126P0937 | MAYO COLLABORATIVE SERVICES, INC. | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $682 | FY2026 |
| 36C26126N0502 | CYTOPATH BIOPSY LAB INC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $72,000 | FY2026 |
| 36C26126N0382 | QUEST DIAGNOSTICS INCORPORATED | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $611,688 | FY2026 |
| 36C26126N0436 | LABORATORY CORPORATION OF AMERICA | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA26115C0031_3600_-NONE-_-NONE- · retrieved 2026-09-26.